Nipocalimab-aahu Drug Asset Due Diligence Report 2026

This Nipocalimab-aahu Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Nipocalimab-aahu can convert its Monoclonal antibody profile and FcRn biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Nipocalimab-aahu (query alias: nipocalimab)
Modality / target	Monoclonal antibody; FcRn; FcRn antagonists, Immunomodulators
Highest global status	Approved
Originator	Janssen Biotech, Inc.
Active developers	Janssen Research & Development LLC, Janssen Pharmaceutical KK, Johnson & Johnson (China) Investment Ltd.

The MCP disease footprint includes Myasthenia Gravis, Warm autoimmune hemolytic anemia, Systemic Lupus Erythematosus. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ISRCTN15146958	Phase 3	Recruiting	600	Not disclosed
NCT07438496	Phase 3	Recruiting	600	Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI)-4 Composite Response at Week 52
NCT07217587	Phase 3	Recruiting	115	Arms 1 and 2: Averaged Mean Percent Change from Baseline in Total Immunoglobulin G (IgG) Levels Over Weeks 8, 10 and 12

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

ASSESSMENT OF NIPOCALIMAB EFFECTS ON FATIGUE IN WARM AUTOIMMUNE HEMOLYTIC ANEMIA: RESULTS FROM THE DOUBLE-BLIND PHASE 2/3 ENERGY TRIAL

Phase 2/3; n=115; evaluation: Positive. Reported fields: FACIT-Fatigue(24-week) = 1.2 point ; FACIT-Fatigue(24-week) = 3.4 point ; FACIT-Fatigue(24-week) = 0.6 point

PHARMACODYNAMIC EFFECT OF NIPOCALIMAB IN WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA) AND CORRELATION WITH CLINICAL IMPROVEMENT

Phase 2/3; n=89; evaluation: Positive. Reported fields: Anti-RBC IgG(Week 1) = 35.0 % ; Anti-RBC IgG(Week 1) = 41.0 %

NIPOCALIMAB FOR WARM AUTOIMMUNE HEMOLYTIC ANEMIA: RESULTS FROM THE PHASE 2/3 RANDOMIZED DOUBLE-BLIND ENERGY STUDY

Phase 2/3; n=115; evaluation: Positive. Reported fields: FACIT-Fatigue(W24) = 1.2 point ( 6.1); FACIT-Fatigue(W24) = 3.4 point ( 7.3); FACIT-Fatigue(W24) = 0.6 point ( 3.4)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Nipocalimab-aahu addresses Myasthenia Gravis, Warm autoimmune hemolytic anemia, Systemic Lupus Erythematosus. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-08-19	Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases	Phase 3	US$6,500.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO